drugset / Trial / NCT01692717

Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide

NCT01692717

Phase 1 Completed 90 enrolled Azidus Brasil
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this clinical study, randomized, crossover is to evaluate the pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide) Laboratory Hypermarcas S / A, in relation to drugs Citalor ® (atovastatina - Pfizer) and Hyzaar ® (losartan + hydrochlorothiazide - Merck Sharp \& Dohme) by comparing the serum concentration of analytes unchanged (AT, LS and HCTZ) in healthy subjects.

Timeline

Start
2013-02-28
Primary completion
2013-05-31
Completion
2013-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Losartan Other / unclassified 50 mg

Indications

No indication recorded.